TL;DR
The dream of getting some of a workout's benefits from a pill just picked up a new contender. BioAge, a company that chooses drug targets by studying human aging data, says it plans to file by the end of 2026 for permission to start testing an "exercise-mimetic" drug in people, aimed at obesity. That makes it at least the third company chasing exercise in a pill, after two others reported early human data this year. Before New Year's, BioAge also expects results from a placebo-controlled trial of about 160 people testing whether its pill can calm chronic inflammation, one of the core processes of aging. Both dates are the company's plans. To see our odds on when an exercise-copying pill reaches people, and the timeline of breakthroughs on the way there, subscribe.
Below the line, for paid subscribers: The full story: where it stands, how we got here and what's dated next; our labeled speculation on what it adds up to; and every source.